Amanda S. Mixon
@mixovida
Followers
188
Following
429
Statuses
116
RT @trtalbotmd: Great time meeting our wonderful Greek partners in the fight against AMR #GAIHN @VUMCHealth @mixovida @CDCgov @vuglobalheal…
0
2
0
RT @DeprescribeUS: Dr. Robert Wahler Jr. @BobWRx presenting during the sponsored research showcase panel. “Support from everyone @Deprescri…
0
1
0
RT @DeprescribeUS: Dr. Amanda Mixon @mixovida and Dr. Sandra Simmons #DrSandraSimmons moderating today’s first sponsored research panel pre…
0
1
0
RT @DeprescribeUS: Dr. Jinjiao Wang @JasmineJinjiaoW presenting sponsored research showcase panel. #USDeN2022Live #DeprescribingGotTalent…
0
1
0
RT @DeprescribeUS: Sponsored research showcase panel with Dr. Daniela Moga @epimoga #USDeN2022Live w/ moderators @mixovida & #DrSandraSimmo…
0
2
0
@MikeSteinman @josh_niznik @DeprescribeUS Less script renewals all around! #DeprescribingResearchChat
1
1
4
@DeprescribeUS A5/2: Would pharma be interested? Maybe if fewer meds mean better adherence-->and better outcomes for disease states. #DeprescribingResearchChat
1
1
4
@DeprescribeUS A5: #Economic and #financial impact are critical to include in outcomes. Otherwise, it may be hard to get all the relevant stakeholders on board with #deprescribing. Not saying it will be easy but needed. #DeprescribingResearchChat
1
1
3
@matthew_growdon @DeprescribeUS Love the ROI idea--if we #deprescribe, then less med errors/harm, ADEs. The cost of those can be estimated. #DeprescribingResearchChat
0
1
2
@DeprescribeUS A4: First, easy entry. We have found many #patients reluctant to join studies. @DThomasstrayer has looked at reasons why. Mostly they don't want anyone but their #clinicians to change meds, rather than recs from study team. #DeprescribingResearchChat
0
1
2
@DeprescribeUS A3/3: maybe our studies will even change attitudes toward future deprescribing for patients, caregivers, and clinicians alike! #DeprescribingResearchChat
0
1
3
@DeprescribeUS A3/2: Outcomes like medication regimen simplicity, less trips to the pharmacy, less cost, better adherence. #DeprescribingResearchChat
1
1
5
@DeprescribeUS A3: What matters to the patient regarding outcomes should matter to us in #research. Quality of life, geriatric syndromes, life space are just some to consider. #DeprescribingResearchChat
1
1
6
@MikeSteinman @matthew_growdon @cynthiaboyd16 @DeprescribeUS We also need the indication why it was started when ordering new meds! Would be great to use indications always, at beginning/middle/end of the medication's life. #DeprescribingResearchChat
1
1
4
@MikeSteinman @heniget @josh_niznik @DeprescribeUS We are trying to look at "stickiness" of deprescribing recommendations, meaning do meds creep back into the med list? #DeprescribingResearchChat
0
1
3
@cynthiaboyd16 @DeprescribeUS And we can draw on the research around behavior change from other studies, ie chronic disease mgmt, clinical inertia, and patient activation. #DeprescribingResearchChat
0
1
6
@DeprescribeUS A2: Not so much a # research method but stakeholders especially specialists are needed to participate in deprescribing research. #DeprescribingResearchChat
0
1
2